Correlation Between Crispr Therapeutics and Arcus Biosciences

Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Arcus Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Arcus Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Crispr Therapeutics AG and Arcus Biosciences, you can compare the effects of market volatilities on Crispr Therapeutics and Arcus Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Arcus Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Arcus Biosciences.

Diversification Opportunities for Crispr Therapeutics and Arcus Biosciences

0.37

Correlation Coefficient

Crispr Therapeutics  Arcus Biosciences

Weak diversification

The 3 months correlation between Crispr and Arcus is 0.37. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Arcus Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Arcus Biosciences and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Arcus Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Arcus Biosciences has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Arcus Biosciences go up and down completely randomly.

Pair Corralation between Crispr Therapeutics and Arcus Biosciences

Given the investment horizon of 90 days Crispr Therapeutics AG is expected to generate 1.34 times more return on investment than Arcus Biosciences. However, Crispr Therapeutics is 1.34 times more volatile than Arcus Biosciences. It trades about 0.18 of its potential returns per unit of risk. Arcus Biosciences is currently generating about 0.15 per unit of risk. If you would invest  4,425  in Crispr Therapeutics AG on May 20, 2025 and sell it today you would earn a total of  1,548  from holding Crispr Therapeutics AG or generate 34.98% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Crispr Therapeutics AG  vs.  Arcus Biosciences

Crispr Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Crispr Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Arcus Biosciences

Risk-Adjusted Performance

Fair

Compared to the overall equity markets, risk-adjusted returns on investments in Arcus Biosciences are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Arcus Biosciences unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Crispr Therapeutics and Arcus Biosciences

The main advantage of trading using opposite Crispr Therapeutics and Arcus Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Arcus Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcus Biosciences will offset losses from the drop in Arcus Biosciences' long position.

The idea behind Crispr Therapeutics AG and Arcus Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.